Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule ^sup 68^Ga-ABY-025 in Breast Cancer Patients

^sup 68^Ga-ABY-025 is a radiolabeled Affibody molecule for in vivo diagnosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer tumors with PET. The aim of the present work was to measure the biodistribution and estimate the radiation dosimetry of ^sup 68^Ga-ABY-025 for 2 diff...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of nuclear medicine (1978) 2016-06, Vol.57 (6), p.867
Hauptverfasser: Sandström, Mattias, Lindskog, Karolina, Velikyan, Irina, Wennborg, Anders, Feldwisch, Joachim, Sandberg, Dan, Tolmachev, Vladimir, Orlova, Anna, Sörensen, Jens, Carlsson, Jörgen, Lindman, Henrik, Lubberink, Mark
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:^sup 68^Ga-ABY-025 is a radiolabeled Affibody molecule for in vivo diagnosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer tumors with PET. The aim of the present work was to measure the biodistribution and estimate the radiation dosimetry of ^sup 68^Ga-ABY-025 for 2 different peptide mass doses in a single group of patients using dynamic and serial whole-body PET/CT. Eight patients with metastatic breast cancer were included. Each patient underwent an abdominal 45-min dynamic and 3 whole-body PET/CT scans at 1, 2, and 4 h after injection of a low peptide dose (LD) and a high peptide dose (HD), with approximately the same amount of radioactivity, in separate investigations 1 wk apart. As input to the absorbed dose calculations, volumes of interest were drawn on all clearly identifiable source organs: liver, kidneys, spleen, descending aorta, and upper large intestine. Absorbed doses were calculated using OLINDA/EXM, version 1.1. Of the major organs, the highest radionuclide uptake at 1, 2, and 4 h after injection was observed in the kidneys and liver. The highest absorbed organ doses were seen in the kidneys, followed by the liver for both LD and HD ^sup 68^Ga-ABY-025. Absorbed doses to liver and kidneys were slightly but significantly higher for LD. Total effective dose was 0.030 ± 0.003 mSv/MBq for LD and 0.028 ± 0.002 mSv/MBq for HD. The effective dose for a typical 200-MBq administration of ^sup 68^Ga-ABY-025 is 6.0 mSv for LD and 5.6 mSv for HD. Therefore, from a radiation dosimetry point of view, HD is preferred for PET/CT evaluation of HER2-expressing breast cancer tumors. These effective doses are somewhat higher than earlier published values for other ^sup 68^Ga-labeled tracers, such as 0.021 ± 0.003 mSv/MBq for ^sup 68^Ga-DOTATATE and ^sup 68^Ga-DOTATOC, mainly because of higher uptake in liver and kidney.
ISSN:0161-5505
1535-5667